Pasireotide for the Medical Management of Feline Hypersomatotropism. (6th May 2015)

• Record Type: Journal Article
• Authors: Scudder, C.J.; Gostelow, R.; Forcada, Y.; Schmid, H.A.; Church, D.; Niessen, S.J.M.
• Is Part Of: Journal of veterinary internal medicine. Volume 29:Number 4(2015:Jul./Aug.)
• Page Start: 1074
• Page End: 1080
• Publication Date: 2015-05-06
• Subjects: Veterinary medicine -- Periodicals; 636.0896
• DOI: 10.1111/jvim.12608
• Languages: English
• ISSNs: 0891-6640

Abstract

<abstract abstract-type="main" id="jvim12608-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="jvim12608-sec-0001" sec-type="section"> <title>Background</title> <p>Feline hypersomatotropism (HST) is a cause of diabetes mellitus in cats. Pasireotide is a novel multireceptor ligand somatostatin analog that improves biochemical control of humans with HST.</p> </sec> <sec id="jvim12608-sec-0002" sec-type="section"> <title>Hypothesis/Objectives</title> <p>Pasireotide improves biochemical control of HST and diabetes mellitus in cats.</p> </sec> <sec id="jvim12608-sec-0003" sec-type="section"> <title>Animals</title> <p>Hypersomatotropism was diagnosed in diabetic cats with serum insulin‐like growth factor‐1 (IGF‐1) concentration >1, 000 ng/mL by radioimmunoassay and pituitary enlargement.</p> </sec> <sec id="jvim12608-sec-0004" sec-type="section"> <title>Methods</title> <p>Insulin‐like growth factor 1 was measured and glycemic control assessed using a 12‐hour blood glucose curve on days 1 and 5. On days 2, 3, and 4, cats received 0.03 mg/kg pasireotide SC q12h. IGF‐1, insulin dose, and estimated insulin sensitivity (product of the area under the blood glucose curve [BGC] and insulin dose) were compared pre‐ and post treatment. Paired <italic>t</italic>‐tests or Wilcoxon signed rank tests were employed for comparison where appropriate; a linear mixed model was created to compare BGC results.</p> </sec> <sec id="jvim12608-sec-0005" sec-type="section"> <title>Results</title> <p>Insulin‐like growth factor 1 decreased in all 12 cats that completed the study (median [range] day 1: 2, 000 ng/mL [1, 051–2, 000] and day 5: 1, 105 ng/mL [380–1, 727], <italic>P</italic> = .002, Wilcoxon signed rank test). Insulin dose was lower on day 5 than on day 1 (mean reduction 1.3 [0–2.7] units/kg/injection, <italic>P</italic> = .003, paired <italic>t</italic>‐test). The product of insulin dose and area under the BGC was lower on day 5 than day 1 (difference of means: 1, 912; SD, 1523; u × mg/dL × hours, <italic>P</italic> = .001; paired <italic>t</italic>‐test). No clinically relevant adverse effects were encountered.</p> </sec> <sec id="jvim12608-sec-0006" sec-type="section"> <title>Conclusions</title> <p>Short‐acting pasireotide rapidly decreased IGF‐1 in cats with HST and insulin‐dependent diabetes. The decrease in IGF‐1 was associated with increased insulin sensitivity.</p> </sec> </abstract>